Vaccines — Key research staff
Prof. Adrian V. S. Hill, NIHR Senior Investigator, Director of the Jenner Institute (Europe’s largest translational vaccine R&D institute) and Wellcome Trust Principal Research Fellow. He has developed novel vaccines and heads a leading programme on infectious disease genetic susceptibility. He leads the malaria project.
Theme Liaison Contact
Centre for Clinical Vaccinology and Tropical Medicine
The Jenner Institute
Oxford OX3 7LE
+44 (0) 1865 617600
Prof. Andrew J Pollard, Jenner Foundation Trustee and James Martin Senior Fellow, Director of the Oxford Vaccine Group (the largest paediatric research group in the UK), Director of the South Central MCRN area (SoCCR), Chairman of the NICE meningitis guidelines development group and Chair of the scientific committee of the World Society for Paediatric Infectious Disease. He leads programmes on meningococcus and vaccination at extremes of age with support from NHS consultants in paediatric vaccinology (Dr Matthew Snape and Dr Dominic Kelly).
Prof. Sarah C. Gilbert, Professor in Vaccinology, Jenner Institute. She is an expert in the construction, production and testing of viral-vectored vaccines and leads the influenza vaccine programme which has developed the first influenza vaccine to demonstrate clinical efficacy through immune responses to conserved influenza antigens. Will lead the vectored Influenza vaccine project.
Prof. Christoph Tang, Glaxo Professor in Cellular Pathology University of Oxford and Honorary Consultant Physician. Expert in the pathogenesis of infections caused by Neisseria meningitidis and Shigella flexneri, and interest is the development and evaluation of protein subunit vaccines against Neisseria meningitidis through structural vaccinology and functional analysis. Will lead the work on novel Meningitis subunit Vaccines.
Prof. Helen McShane, Professor in Vaccinology, Wellcome Trust Senior Clinical Research Fellow and Honorary Consultant Physician. She leads the TB vaccine programme within the Jenner Institute, and has led the development of the most clinically advanced new TB vaccine in the world, MVA85A. Will lead the Tuberculosis vaccines project.
Dr Lucy Dorrell, HEFCE Senior Clinical Lecturer. Leads a translational research programme on therapeutic immunomodulation HIV-1 infection. She has extensive experience in Phase I trials of prophylactic and therapeutic HIV vaccine candidates and is developing new biomarkers to assess HIV immune control. Will lead the therapeutic HIV vaccines work.
Dr Thomas Hanke has designed and made several new HIV vaccine candidates including that encoding the promising HIVconsv insert. He will lead the HIV prophylactic vaccines project.
Prof. Sir Andrew McMichael directs the Weatherall Institute for Molecular Medicine, developed the rationale for T cell based influenza vaccines, and has led the Oxford HIV vaccine programme for more than ten years. He will provide important oversight for the HIV and influenza vaccines programmes.